SRT 1720

Key Product Details

Product Description

SRT 1720 is selective SIRT 1 activator (EC₅₀ = 0.16 μM). SRT 1720 inhibits growth of bladder cancer organoids and xenografts (IC₅₀ = 0.35 μM) and induces autophagy. In vitro, SRT 1720 increases mitochondrial biogenesis and recovery after oxidation injury and reduces palmitate-induced insulin resistance. Also improves survival and healthspan of obese mice.

Product Specifications for SRT 1720

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SRT 1720

The following data is based on the product molecular weight 469.56.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	42.59 mL	212.97 mL	425.93 mL
0.25 mM	8.52 mL	42.59 mL	85.19 mL
0.5 mM	4.26 mL	21.30 mL	42.59 mL
2.5 mM	0.85 mL	4.26 mL	8.52 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Funk SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J.Pharmacol.Exp.Ther. 2010 PMID: 20103585
• Luo Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress. Int.J.Mol.Med. 2019 PMID: 30864731
• Paramesha Sirt1 and Sirt3 activation improved cardiac function of diabetic rats via modulation of mitochondrial function. Antioxidants (Basel) 2021 PMID: 33668369
• Tan SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene 2021 PMID: 34471236

Product Documents for SRT 1720